Emerging Company Profiles

Emerging Company Profile: The UK biotech is working to expedite its portfolio of acquired drug candidates for cancer through the clinic before out-licensing to big pharma in a bid to bring patients the treatments they need sooner rather than later.

Emerging Company Profile: The US biotech is advancing its lead candidate into a Phase Ib psoriasis trial as it works to validate its bacterial metabolite-based drug platform, which exemplifies a new generation of microbiome technology.

Emerging Company Profile: The Scottish biotech is the only firm targeting the ANAX1 protein with plans to initiate a modular Phase I trial that could look at multiple tumor types before expanding to the autoimmune space.

Emerging Company Profile: The biotech plans to enter the clinic next year with a gene therapy targeting the E2F4 protein in the hopes of halting Alzheimer’s disease progression and restoring lost function.

The German biotech plans to prevent chemotherapy-induced hearing loss and treat chronic hearing loss by targeting a potassium channel in the ear’s sensory hair cells as it tackles a widespread but side-lined area.

Emerging Company Profile: Mini-proteins offer some of the capabilities of small molecules and antibodies with fewer limitations, Ordaõs claims. The biotech wants to lead a paradigm shift from discovery to design.

Emerging Company Profile: The Danish firm has achieved proof-of-mechanism for its first-in-class CIC-1 inhibitor asset in myasthenia gravis as it advances a pipeline of transformative therapies for rare neuromuscular disorders.

The UK biotech hopes to address a fast-progressing form of dementia that affects people earlier in life with a supplemental gene therapy delivered directly to the brain’s information centre.

Emerging Company Profile: US firm Peptilogics is advancing through the clinic with its lead orthopedic anti-infective drug candidate based on an AI platform that utilizes algorithms to improve peptide design.

Emerging Company Profile: The French firm, which is developing the lead CTP synthase 1 inhibitor in the pipeline, plans to address a range of cancers with its highly selective approach.

Emerging Company Profile: The French biotech is developing a constrained peptide that targets an interaction in body fat tissue in the hopes of treating type 2 diabetes.

Emerging company profile: The US biotech is wrapping up a Phase I trial for its lead pancreatic cancer program at the end of this year and hopes to expand its precision drug-device combination platform to a range of other solid tumors.